First Header Logo Second Header Logo

Connection

Reese Randle to Prognosis

This is a "connection" page, showing publications Reese Randle has written about Prognosis.
Connection Strength

0.578
  1. Randle RW, Bates MF, Schneider DF, Sippel RS, Pitt SC. Survival in patients with medullary thyroid cancer after less than the recommended initial operation. J Surg Oncol. 2018 May; 117(6):1211-1216.
    View in: PubMed
    Score: 0.111
  2. Randle RW, Bushman NM, Orne J, Balentine CJ, Wendt E, Saucke M, Pitt SC, Macdonald CL, Connor NP, Sippel RS. Papillary Thyroid Cancer: The Good and Bad of the "Good Cancer". Thyroid. 2017 07; 27(7):902-907.
    View in: PubMed
    Score: 0.107
  3. Randle RW, Balentine CJ, Leverson GE, Havlena JA, Sippel RS, Schneider DF, Pitt SC. Trends in the presentation, treatment, and survival of patients with medullary thyroid cancer over the past 30 years. Surgery. 2017 01; 161(1):137-146.
    View in: PubMed
    Score: 0.103
  4. Randle RW, Doud AN, Levine EA, Clark CJ, Swett KR, Shen P, Stewart JH, Votanopoulos KI. Peritoneal surface disease with synchronous hepatic involvement treated with Cytoreductive Surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC). Ann Surg Oncol. 2015 May; 22(5):1634-8.
    View in: PubMed
    Score: 0.088
  5. Randle RW, Swett KR, Swords DS, Shen P, Stewart JH, Levine EA, Votanopoulos KI. Efficacy of cytoreductive surgery with hyperthermic intraperitoneal chemotherapy in the management of malignant ascites. Ann Surg Oncol. 2014 May; 21(5):1474-9.
    View in: PubMed
    Score: 0.082
  6. Votanopoulos KI, Russell G, Randle RW, Shen P, Stewart JH, Levine EA. Peritoneal surface disease (PSD) from appendiceal cancer treated with cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC): overview of 481 cases. Ann Surg Oncol. 2015 Apr; 22(4):1274-9.
    View in: PubMed
    Score: 0.022
  7. Doud AN, Randle RW, Clark CJ, Levine EA, Swett KR, Shen P, Stewart JH, Votanopoulos KI. Impact of distal pancreatectomy on outcomes of peritoneal surface disease treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Ann Surg Oncol. 2015 May; 22(5):1645-50.
    View in: PubMed
    Score: 0.022
  8. Ahmed S, Levine EA, Randle RW, Swett KR, Shen P, Stewart JH, Votanopoulos KI. Significance of diaphragmatic resections and thoracic chemoperfusion on outcomes of peritoneal surface disease treated with cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC). Ann Surg Oncol. 2014 Dec; 21(13):4226-31.
    View in: PubMed
    Score: 0.022
  9. Votanopoulos KI, Randle RW, Craven B, Swett KR, Levine EA, Shen P, Stewart JH, Mirzazadeh M. Significance of urinary tract involvement in patients treated with cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC). Ann Surg Oncol. 2014 Mar; 21(3):868-74.
    View in: PubMed
    Score: 0.021
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.